Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders

US9428506B2 · kind B2 · utility

Assignee

• INTRA-CELLULAR THERAPIES, INC. · US

Inventors

• Sharon Mates · New York, US
• Robert E. Davis · San Diego, US
• Peng Li · New York, US
• Lawrence P. Wennogle · Fryeburg, US
• Kimberly VANOVER · New York, US

Key dates

• Filing date: Apr 14, 2013
• Grant date: Aug 30, 2016
• Expiry date: Apr 14, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to particular substituted heterocycle fused gamma-carbolines, of Formula I, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems, such as disease of the central nervous system.